Search for Clinical Trial Results
Lymphoma, T-Cell - 77 Studies Found
Status | Study |
Completed |
Study Name: A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2005-09-13 Interventions: Drug: ONTAK (denileukin diftitox, DAB389 IL-2) Ontak + CHOP every 3 weeks. |
No longer available |
Study Name: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) Condition: Lymphoma, T-Cell, Cutaneous Date: 2007-01-05 Interventions: Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |
Completed |
Study Name: Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2012-08-30 Interventions:
|
Completed |
Study Name: A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas Condition: Lymphoma, T-Cell, Peripheral Date: 2016-05-23 Interventions: Other: No Intervention |
Active, not recruiting |
Study Name: A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) Condition: Lymphoma, T-cell, Peripheral Date: 2011-10-18 Interventions: Drug: Romidepsin Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle |
Terminated |
Study Name: LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma Condition: T-Cell Lymphoma Date: 2005-09-08 Interventions: Drug: Doxil, Methotrexate, L-Asparaginase, Prednisone |
Completed |
Study Name: A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Condition: T Cell Lymphoma Date: 2012-03-13 Interventions: Drug: Sorafenib Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be |
Completed |
Study Name: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma Condition: T-cell Lymphoma Date: 2009-08-14 Interventions: Drug: Bendamustine Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 day |
Completed |
Study Name: Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Condition: T Cell Lymphoma Date: 2008-11-21 Interventions: Drug: Fostamatinib Disodium 200 mg PO BID Other Name |
Recruiting |
Study Name: Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2015-08-26 Interventions: Drug: MK-3475 Other Name: Pembrolizumab |